Altre lingue PainReform Ltd.

Azioni

PRFX

IL0011651580

Tempo differito Nasdaq Altri mercati azionari 17:00:17 28/06/2024			Variaz. 5gg	Var. 1 gen.
0,478 ^USD	-4,05%		-4,19%	-82,62%

26/06	PainReform Ltd. Completa l'arruolamento nella seconda parte dello studio di Fase 3 sulla bunionectomia per Prf-110	CI
15/05	PainReform Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110	26/06
PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110	26/06
Certain Warrants of PainReform Ltd. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	18/06
Certain Ordinary Shares of PainReform Ltd. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	18/06
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification	31/05
PAINREFORM : CONDENSED FINANCIAL STATEMENTS - Form 6-K	15/05
PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
PainReform Provides Business Update for the First Quarter of 2024	15/05
PainReform : CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com	08/05
PainReform Announces Closing of $4 Million Public Offering	18/04
PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	16/04
PainReform Announces Pricing of $4 Million Public Offering	16/04
PainReform : CEO IlanHadar Interviewed on “The Big Biz Show”	14/04
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110	09/04
PainReform : Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions	09/04
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy	02/04
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy	02/04
PainReform : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS - Form 6-K	07/03
PainReform : Investors Presentation – March 2024	03/03
PainReform Provides Year-End Business Update	01/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue PainReform Ltd.

Azioni

PRFX

IL0011651580

Altre lingue

Filtri